Astria commences Phase III hereditary angioedema therapy trial [Yahoo! Finance]
Astria Therapeutics, Inc. (ATXS)
Company Research
Source: Yahoo! Finance
The global, double-blind trial is designed to assess the safety and efficacy of the therapy over six months. It will evaluate navenibart in up to 135 adults and ten adolescents with HAE type 1 or type 2. Adult subjects will be administered with one of three therapy dosing regimens or a placebo in the different treatment arms. The initial arm will involve a 600mg dose of the therapy, followed by 300mg every three months (Q3M). The second arm will involve a 600mg dose every six months, and the last arm will use 600mg given Q3M. Adolescent subjects of the trial will be given a specific dosing schedule involving 600mg initially, followed by 300mg given Q3M. The trial's primary endpoint is the time-normalised monthly rate of HAE attacks at the six
Read more
Impact Snapshot
Event Time:
ATXS
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ATXS alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ATXS alerts
High impacting Astria Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
ATXS
News
- Astria Therapeutics, Inc. (NASDAQ: ATXS) had its "outperform" rating re-affirmed by analysts at Wedbush.MarketBeat
- Astria Therapeutics, Inc. (NASDAQ: ATXS) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $16.00 price target on the stock.MarketBeat
- Astria Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides a Corporate Update [Yahoo! Finance]Yahoo! Finance
- Astria Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides a Corporate UpdateBusiness Wire
- Astria Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)Business Wire
ATXS
Earnings
- 3/11/25 - Beat
ATXS
Sec Filings
- 3/25/25 - Form 4
- 3/25/25 - Form 4
- 3/25/25 - Form 4
- ATXS's page on the SEC website